| 发明名称 | Monoclonal antibody directed against CXCR5 | ||
| 摘要 | The invention relates to monoclonal antibodies against human CXCR5 and to their use in the treatment of autoimmune or inflammatory diseases, as well as cancers. | ||
| 申请公布号 | US9534054(B2) | 申请公布日期 | 2017.01.03 |
| 申请号 | US201414787478 | 申请日期 | 2014.04.30 |
| 申请人 | ARES TRADING S.A. | 发明人 | Power Christine;Leger Olivier;Bradfield Paul;Nastri Horacio G.;Iffland Christel;An Qi |
| 分类号 | A61K39/00;A61K39/395;A61K51/10;C07K16/28 | 主分类号 | A61K39/00 |
| 代理机构 | Saliwanchik, Lloyd & Eisenschenk | 代理人 | Saliwanchik, Lloyd & Eisenschenk |
| 主权项 | 1. A monoclonal antibody, or an antigen-binding fragment thereof, that binds to CXCR5, which comprises: a) a heavy chain variable domain comprising H-CDR1, H-CDR2 and H-CDR3, wherein: i) H-CDR1 comprises SEQ ID NO: 8 or 9;ii) H-CDR2 comprises SEQ ID NO: 10 or 11; andiii) H-CDR3 comprises SEQ ID NO: 12 or 13; and b) a light chain variable domain comprising L-CDR1 L-CDR2 and L-CDR3, wherein: i) L-CDR1 comprises SEQ ID NO: 14 or 15;ii) L-CDR2 comprises SEQ ID NO: 16 or 17; andiii) L-CDR3 comprises SEQ ID NO: 18 or 19. | ||
| 地址 | Aubonne CH | ||